Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA

Future Oncology

Volumn 13, Issue 19, 2017, Pages 1699-1710

  Lance Cowey, C ^a   Mahnke, Lisa ^b   Espirito, Janet ^c   Helwig, Christoph ^d   Oksen, Dina ^d   Bharmal, Murtuza ^d  

^a TEXAS ONCOLOGY   (United States)

^b EMD SERONO INC   (United States)

^c McKesson Specialty Health   (United States)

^d MERCK KGAA   (Germany)

Author keywords

chemotherapy; immunotherapy; Merkel cell carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; PACLITAXEL; TOPOTECAN; VINCRISTINE; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; MALE; MERKEL CELL CARCINOMA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; CANCER STAGING; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETREATMENT; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, MERKEL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; RETREATMENT; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85028531190     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon-2017-0187     Document Type: Article

References (34)

1. Lemos BD, Storer BE, Iyer JG et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the frst consensus staging system. J. Am. Acad. Dermatol. 63(5), 751-761 (2010).
2. Saini AT, Miles BA. Merkel cell carcinoma of the head and neck: pathogenesis, current and emerging treatment options. Onco. Targets Ther. 8, 2157-2167 (2015).
3. Koljonen V. Merkel cell carcinoma. World J. Surg. Oncol. 4, 7 (2006).
4. Lemos B, Nghiem P. Merkel cell carcinoma: more deaths but still no pathway to blame. J. Invest. Dermatol. 127(9), 2100-2103 (2007).
5. Heath M, Jaimes N, Lemos B et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J. Am. Acad. Dermatol. 58(3), 375-381 (2008).
6. Santamaria-Barria JA, Boland GM, Yeap BY et al. Merkel cell carcinoma: 30-year experience from a single institution. Ann. Surg. Oncol. 20(4), 1365-1373 (2013).
7. Allen PJ, Bowne WB, Jaques DP, Brennan MF, Busam K, Coit DG. Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J. Clin. Oncol. 23(10), 2300-2309 (2005).
8. Bavencio (avelumab) injection, package insert. Merck KGaA, Darmstadt, Germany (2017).
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Merkel cell carcinoma. V1 (2017). www.nccn.org/professionals/physician-gls
10. Leech SN, Kolar AJ, Barrett PD, Sinclair SA, Leonard N. Merkel cell carcinoma can be distinguished from metastatic small cell carcinoma using antibodies to cytokeratin 20 and thyroid transcription factor 1. J. Clin. Pathol. 54(9), 727-729 (2001).
11. Lebbe C, Becker JC, Grob JJ et al. Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur. J. Cancer 51(16), 2396-2403 (2015).
12. Iyer JG, Blom A, Doumani R et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 5(9), 2294-2301 (2016).
13. Nghiem P, Kaufman H, Bharmal M, Mahnke L, Phatak H, Becker J. Systemic literature review of effcacy and safety outcomes of chemotherapy regimens in patients with metastatic MCC. Future Oncol. doi: 10.2217/fon-2017-0072 (2017) (Epub ahead of print).
14. Tai PT, Yu E, Winquist E et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J. Clin. Oncol. 18(12), 2493-2499 (2000).
15. Voog E, Biron P, Martin JP, Blay JY. Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer 85(12), 2589-2595 (1999).
16. Sharma D, Flora G, Grunberg SM. Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature. Am. J. Clin. Oncol. 14(2), 166-169 (1991).
17. Satpute SR, Ammakkanavar NR, Einhorn LH. Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. J. Clin. Oncol. 32(Suppl.), 9049 (2014).
18. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319(5866), 1096-1100 (2008).
19. Goh G, Walradt T, Markarov V et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7(3), 3403-3415 (2016).
20. Paulson KG, Iyer JG, Blom A et al. Systemic immune suppression predicts diminished Merkel cell carcinoma-specifc survival independent of stage. J. Invest. Dermatol. 133(3), 642-646 (2013).
21. + lymphocyte intratumoral infltration as a stage-independent predictor of Merkel cell carcinoma survival: a population-based study. Am. J. Clin. Pathol. 142(4), 452-458 (2014).
22. +) T-cell responses identifed in Merkel cell carcinomas and blood. Clin. Cancer Res. 17(21), 6671-6680 (2011).
23. Afanasiev OK, Yelistratova L, Miller N et al. Merkel polyomavirus-specifc T cells fuctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin. Cancer Res. 19(19), 5351-5360 (2013).
24. Kaufman HL, Russell J, Hamid O et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, Phase II trial. Lancet Oncol. 17(10), 1374-1385 (2016).
25. Nghiem PT, Bhatia S, Lipson EJ et al. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N. Engl. J. Med. 374(26), 2542-2552 (2016).
26. Kaufman HL, Russell JS, Hamid O et al. Durable responses to avelumab (anti-PD-L1) in patients with Merkel cell carcinoma progressed after chemotherapy: 1-year effcacy update. Presented at: AACR Annual Meeting 2017. Washington, DC, USA, 1-5 April 2017 (Abstract CT079).
27. Topalian SL, Bhatia S, Hollebecque A et al. Non-comparative, open-label, multiple cohort, Phase I/II study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): effcacy and safety in Merkel cell carcinoma (MCC). Presented at: AACR Annual Meeting 2017. Washington, DC, USA, 1-5 April 2017 (Abstract CT074).
28. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228-247 (2009).
29. Becker J, Lorenz E, Haas G et al. Evaluation of real world treatment outcomes in patients with metastatic Merkel cell carcinoma (MCC) following second line chemotherapy. Ann. Oncol. 26(Suppl. 3), Abstract 2602 (2016).
30. Harms KL, Healy MA, Nghiem P et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann. Surg. Oncol. 23(11), 3564-3571 (2016).
31. Harms PW, Vats P, Verhaegen ME et al. The distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res. 75(18), 3720-3727 (2015).
32. Wong SQ, Waldeck K, Vergara IA et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 75(24), 5228-5234 (2015).
33. Sihto H, Bohling T, Kavola H et al. Tumor infltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin. Cancer Res. 18(10), 2872-2881 (2012).
34. Behr DS, Peitsch WK, Hametner C et al. Prognostic value of immune cell infltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. Int. J. Clin. Exp. Pathol. 7(11), 7610-7621 (2014).